VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Axsome Therapeutics Executive Compensation (FY25)

AXSM · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Herriot Tabuteau
Latest say-on-pay support
=
June 5, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Axsome Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 9, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Axsome Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
307 figures on this page: 300 cited to the filing that reported them, 7 calculated from figures it prints. See the citations

More on Axsome Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Herriot Tabuteau: $10,364,688 → $10,283,492 (0.8% lower)
CEO pay ratio: 21:1 → 23:1 (9.5% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Axsome Therapeutics' chief executive and what were they paid?
Herriot Tabuteau was paid $10,283,492 in total compensation as Chief Executive Officer, President, and Chairman of the Board for fiscal 2025. Compared with the $10,364,688 reported for fiscal 2024, Tabuteau's total was 0.8% lower.
What was Axsome Therapeutics' say-on-pay result?
The say-on-pay proposal drew 97.1% of votes cast including abstentions in favor at the meeting held June 5, 2026 for fiscal 2025.
Which companies are in Axsome Therapeutics' peer group?
The disclosed peer group names Apellis Pharmaceuticals, Inc., BridgeBio Pharma, Inc., Collegium Pharmaceutical, Inc. and Zai Lab Limited.
What is Axsome Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 23:1, against median employee compensation of $437,980.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Herriot Tabuteau
Chief Executive Officer, President, and Chairman of the Board
◇—◇◇◇—◇◇
Mark Jacobson
M.A. Chief Operating Officer
◇—◇◇◇—◇◇
Nick Pizzie
Chief Financial Officer
◇—◇◇◇—◇◇
Hunter Murdock
General Counsel
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Herriot Tabuteau
Chief Executive Officer, President, and Chairman of the Board
◇—◇◇◇—◇◇
Mark Jacobson
M.A. Chief Operating Officer
◇—◇◇◇—◇◇
Ari Maizel
Chief Commercial Officer
◇—◇◇◇——◇
Nick Pizzie
Chief Financial Officer
◇—◇◇◇—◇◇
Hunter Murdock
General Counsel
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Herriot Tabuteau
Chief Executive Officer, President and Chairman of the Board
◇—◇◇◇—◇◇
Mark Jacobson
Chief Operating Officer
◇—◇◇◇—◇◇
Nick Pizzie
Chief Financial Officer
◇—◇◇◇—◇◇
Hunter Murdock
General Counsel
◇—◇◇◇—◇◇
Ari Maizel
Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Herriot Tabuteau
Chief Executive Officer, President, and Chairman of the Board
◇—◇◇◇—◇◇
Mark Jacobson
Chief Operating Officer
◇—◇◇◇—◇◇
Nick Pizzie
Chief Financial Officer
◇—◇◇◇—◇◇
Hunter Murdock
General Counsel
◇—◇◇◇—◇◇
Ari Maizel
Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Ari MaizelPSU◇◇◇—◇—◇
Ari MaizelRSU◇——◇——◇
Ari MaizelOPTION◇——◇—◇◇
Herriot TabuteauOPTION◇——◇—◇◇
Herriot TabuteauRSU◇——◇——◇
Herriot TabuteauPSU◇◇◇—◇—◇
Hunter MurdockRSU◇——◇——◇
Mark JacobsonOPTION◇——◇—◇◇
Mark JacobsonPSU◇◇◇—◇—◇
Mark JacobsonRSU◇——◇——◇
Nick PizzieOPTION◇——◇—◇◇
Nick PizziePSU◇◇◇—◇—◇
Nick PizzieRSU◇——◇——◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Nick PizzieRSU◇=——
Option◇—◇2/27/2034
RSU◇◇——
Option◇—◇3/2/2033
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/21/2035
Option◇—◇3/4/2032
Herriot TabuteauOption◇—◇2/27/2034
RSU◇◇——
Option◇—◇3/2/2033
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/21/2035
Option◇—◇3/4/2032
Mark JacobsonOption◇—◇2/27/2034
RSU◇◇——
Option◇—◇3/2/2033
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/21/2035
Option◇—◇3/4/2032
Ari MaizelOption◇—◇9/25/2033
Option◇—◇2/27/2034
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/21/2035
Hunter MurdockOption◇—◇2/27/2034
RSU◇◇——
Option◇—◇3/2/2033
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/21/2035
Option◇—◇3/4/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Hunter Murdock
General Counsel · Terms as described in the company’s compensation discussion
Severance multiple◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Coleman
Lead independent director
◇◇◇———◇
Mark Saad
◇◇◇———◇
Roger Jeffs
◇◇◇———◇
Susan Mahony
◇◇◇———◇
Herriot Tabuteau served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Apellis Pharmaceuticals, Inc. APLS
  • BridgeBio Pharma, Inc. BBIO
  • Collegium Pharmaceutical, Inc. COLL
  • Zai Lab Limited ZLAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 5, 2026=◇◇◇
2024June 6, 2025=◇◇◇
2023June 7, 2024=◇◇◇
2022June 2, 2023=◇◇◇
2021June 3, 2022=◇◇◇
2020June 4, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Herriot Tabuteau (Chief Executive Officer, President, and Chairman of the Board), FY2025 total compensation $10,283,492 (base salary $835,000) [exec_comp, SEC accession 0001193125-26-177610, filed 2026-04-24]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Axsome Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Axsome Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Axsome Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Axsome Therapeutics' disclosed peer group is defensible, who names Axsome Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
307 figures on this page: 300 cited to the filing that reported them, 7 calculated from figures it prints.
300 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001193125-26-264043
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-177610
    2025 Grants of Plan-Based Awards · Compensation Discussion and Analysis · Director Compensation · Outstanding Equity Awards as of December 31, 2025 · and 1 more section
  3. 0000950170-25-083793
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-058781
    Summary Compensation Table
  5. 0000950170-24-071960
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-24-049221
    Summary Compensation Table
  7. 0000950170-23-027059
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000950170-22-011269
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001564590-21-031994
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Axsome Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AXSM (accessed 2026).
Short form: data: Velarion

The paid brief for Axsome Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Axsome Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Axsome Therapeutics discloses

The companies named in AXSM's own disclosed peer group.

Apellis Pharmaceuticals, Inc.BridgeBio Pharma, Inc.Collegium Pharmaceutical, Inc.Zai Lab Limited

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy